$19.08
+0.21 (+1.09%)
Open$19.17
Previous Close$18.88
Day High$19.56
Day Low$18.62
52W High$29.28
52W Low$5.55
Volume—
Avg Volume208.5K
Market Cap626.54M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+43.6% upside
Current
$19.08
$19.08
Target
$27.40
$27.40
$23.46
$27.40 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 66.09M | 69.56M | 73.83M |
| Net Income | 7.65M | 9.76M | 11.38M |
| Profit Margin | 11.6% | 14.0% | 15.4% |
| EBITDA | 12.79M | 14.57M | 15.15M |
| Free Cash Flow | 6.98M | 8.54M | 10.02M |
| Rev Growth | +12.3% | +24.1% | -0.1% |
| Debt/Equity | 0.76 | 0.65 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |